Horizon Pharma plc (Nasdaq: HZNP) announced that it has received a Notice of Allowance from the United States Patent and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Litigation

Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAVICTI(R) (glycerol phenylbutyrate) Oral LiquidMarch 16, 2016 7:00 AM IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Horizon Pharma plc And Encourages Investors With Losses To Contact the FirmMarch 15, 2016 5:07 PM Horizon Pharma (HZNP) Falls Amid Lower Outlook from ValeantMarch 15, 2016 9:51 AM Horizon Pharma (HZNP) Receives USPTO Notice of Allowance for VIMOVO-Related PatentMarch 14, 2016 7:19 AM Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO(R) (naproxen/esomeprazole) Delayed Release TabletsMarch 14, 2016 7:00 AM